Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. HUTCHMED (China) Limited
  6. News
  7. Summary
    HCM   KYG4672N1198

HUTCHMED (CHINA) LIMITED

(HCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Hutchmed, Innovent Study of Tyvyt plus Elunate Show Positive Results as Third Line Treatment for Advanced Colorectal Cancer

06/07/2021 | 04:33am EST


© MT Newswires 2021
All news about HUTCHMED (CHINA) LIMITED
06:22aHUTCHMED CHINA : Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Add..
PU
02:32aHutchmed's Two Cancer Therapies Included in China's Drug Reimbursement List
MT
02:01aChina to Add Hutchmed's Tumor Drug in 2022 National Reimbursement Drug List, Retain Fir..
MT
12/03HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition..
AQ
11/24Health Care Stocks Mixed Premarket Wednesday
MT
11/24HUTCHMED CHINA : and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO®..
PU
11/24Hutchmed, AstraZeneca Begin Phase 3 Lung Cancer Trial in China
MT
11/24AstraZeneca, Hutchmed Start Late-Stage Trial of Lung Cancer Combo in China
MT
11/23Hutchmed, AstraZeneca Dose First Patient in China Phase III Study of Combination Therap..
MT
11/23HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Comb..
AQ
More news
Analyst Recommendations on HUTCHMED (CHINA) LIMITED
More recommendations
Financials (USD)
Sales 2021 336 M - -
Net income 2021 -261 M - -
Net cash 2021 484 M - -
P/E ratio 2021 -19,2x
Yield 2021 -
Capitalization 5 756 M 5 752 M -
EV / Sales 2021 15,7x
EV / Sales 2022 11,7x
Nbr of Employees 1 280
Free-Float 51,3%
Chart HUTCHMED (CHINA) LIMITED
Duration : Period :
HUTCHMED (China) Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HUTCHMED (CHINA) LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 6,72 $
Average target price 8,99 $
Spread / Average Target 33,8%
EPS Revisions
Managers and Directors
Christian Hogg Chief Executive Officer & Executive Director
Chig Fung Cheng Chief Financial Officer & Executive Director
Chi Keung To Executive Chairman
Wei Guo Su Executive Director & Chief Scientific Officer
Marek Kania Chief Medical Officer & Managing Director
Sector and Competitors
1st jan.Capi. (M$)
HUTCHMED (CHINA) LIMITED10.22%5 779
JOHNSON & JOHNSON-0.18%413 555
ROCHE HOLDING AG17.62%341 509
PFIZER, INC.44.09%297 706
NOVO NORDISK A/S64.51%243 534
ELI LILLY AND COMPANY47.55%224 726